Leerink Partnrs Predicts Sanofi's Q1 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Sanofi in a research report issued on Sunday, March 30th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $0.88 for the quarter, up from their previous forecast of $0.85. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's Q2 2025 earnings at $0.93 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $4.39 EPS, FY2026 earnings at $5.00 EPS, FY2027 earnings at $5.03 EPS, FY2028 earnings at $5.49 EPS and FY2029 earnings at $6.02 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

SNY has been the subject of several other reports. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $62.50.

Remove Ads

Sanofi Stock Up 1.2 %

NASDAQ:SNY traded up $0.67 on Tuesday, hitting $54.62. The stock had a trading volume of 1,842,025 shares, compared to its average volume of 2,275,919. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The firm's fifty day simple moving average is $55.33 and its two-hundred day simple moving average is $52.74. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market cap of $138.62 billion, a P/E ratio of 21.94, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SNY. Invesco Ltd. lifted its holdings in Sanofi by 3.5% during the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after buying an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the period. Boston Partners boosted its holdings in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. grew its stake in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after buying an additional 369,530 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.